Solid Biosciences Inc.
www.solidbio.com
Latest From Solid Biosciences Inc.
Roche $4.8bn Buy Sparks Hemophilia Gene Therapy Race
The Swiss major's proposed acquisition of Spark Therapeutics gives it a leading seat at the table in the emerging field of gene therapy.
Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019
Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.
Cerevel Launches With Pfizer's Early CNS Assets And $350m From Bain Capital
Pfizer ended its early neuroscience R&D work earlier this year, but will retain a 25% stake in the start-up, which may begin a Phase III Parkinson's disease study in 2019. This is the second time Bain has financed a Pfizer spin-out.
Sarepta Commits To Rapid, Thorough Pivotal Study For DMD Gene Therapy Based On Functional Improvements
The company presented encouraging data on functional assessments of four boys treated with a micro-dystrophin gene therapy at the World Muscle Society, furthering momentum around the program.
Company Information
- Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Alias(es)
- Solid Ventures
- Solid Biosciences LLC
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Solid Biosciences Inc.
- Senior Management
-
Ilan Ganot, CEO
Jennifer Ziolkowski, CFO
Carl Morris , PhD, CSO
Joel Schneider, PhD, CTO, Head, Exploratory R&D
Jorge A Quiroz, MD, CMO
Alvaro Amorrortu, COO - Contact Info
-
Solid Biosciences Inc.
Phone: (617) 337-4680
161 First St.
3rd Floor
Cambridge, MA 02142
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice